Syschem (India) Ltd manufactures active pharmaceutical ingredients (APIs) and intermediates, primarily antibiotics like Amoxycillin and Ampicillin, and provides solvent distillation services for the pharmaceutical industry.
The company operates in a highly commoditized generic API market with no evidence of pricing power, as reflected by negative average net margins and ROCE. While revenue has grown significantly, the lack of profitability suggests a lack of any structural cost advantage or brand-based moat.
Capital has been deployed into capacity expansion and new plant setups, yet these investments have failed to generate positive returns on capital over the period. Recent actions include a rights issue and preferential allotment of warrants to promoters to fund working capital and expansion.
The company collapsed after its reliance on promoter-linked entities turned from a crutch into a noose. Despite rapid revenue growth, the business never achieved self-sustaining profitability, and the capital raised through dilutive warrants was drained by inefficient working capital and related-party dealings. When the ongoing insolvency litigation reached a breaking point and the corporate guarantees for promoter concerns were called, the lack of genuine cash flow left the company unable to service its obligations, leading to a total wipeout of minority shareholder value.
RichFakir rates Syschem (India) Ltd's business quality as poor — 29/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Syschem (India) Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Syschem (India) Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Syschem (India) Ltd's fair value is about ₹14 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →